The Swiss-headquartered company has scaled up its operations to become a leading contract development and manufacturing organization focused on profitable growth.
With capabilities supporting its next-generation ADC pipeline scaled up externally, Sutro Biopharma’s operations in San Carlos, California will cease this year.
While the $925 million acquisition of Biovectra was completed in September, Agilent is bringing the Canadian CDMO up to its standards in terms of process and quality.
The company is investing $1 billion in its Songdo Bio Campus in South Korea, with Plant 1 scheduled for completion this year and full-scale commercial production by 2027.
By automating and digitizing critical processes, Ori’s platform is designed to streamline manufacturing workflows and overcome bottlenecks that limit patient access.
The Montreal-based company is at risk from potential tariffs from President Donald Trump and Canada’s government that could adversely affect its financial results.
CEO Ulrich Faessler called the U.S. investment a “major step forward” in positioning SHL as the only autoinjector manufacturer operating across three continents.
Brazil, Russia, India, China, South Africa (BRICS) members are positioning themselves to offset the pressures from U.S. trade policies, says analytics firm GlobalData.
While Canada is not the largest supplier of U.S. pharmaceuticals, proposed tariffs could significantly increase costs and disrupt supply chains, according to a new analysis.
What’s next for pharma manufacturing in 2025? As the industry continues to respond to new scientific breakthroughs, supply chain pressures, and geopolitical tensions, the...
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
Discover the latest contract manufacturing key trends for the life science industry, including compliance, digital transformation and more. Don't let your organization fall behind...
